Benzodiazepines and Z-Drugs in Pregnancy
The use of benzodiazepines (BZDs) during pregnancy has been considered for a long time at high risk of inducing some structural birth defects, particularly oral cleft. The aim of this chapter is to briefly present the best recent studies focusing on the risks of major malformations (MMs) and perinatal complications (PCs) in newborns of pregnant women exposed to BZDs and Z-drugs during pregnancy. In the current literature, there is a substantial agreement that BZD exposure during the first trimester of pregnancy seems not to be associated with an increasing risk of MMs. However, during the second and third trimester of pregnancy, BZD exposure may be associated with some neonatal adverse reactions, such as a withdrawal syndrome and an infant floppy syndrome. No increase in the risk of neurobehavioral and/or cognitive disorders in infants exposed during pregnancy has been observed in the few studies focusing on this issue. Less information concerning the foetal and neonatal safety of Z-drug exposure during pregnancy has been so far published; however, the few data available have not reported an increased risk of MMs and neonatal adverse outcomes in infants exposed in utero to these drugs.
General principles in prescribing and clinical recommendations on the management of BZDs and Z-drugs during pregnancy are provided, according to the recent suggestions coming from the international guidelines and expert opinions.
KeywordsBenzodiazepines Z-drugs Clinical psychopharmacology Pregnancy Congenital malformations Perinatal complications
- 1.Galbally M, Snellen M, Lewis A. Psychopharmacology and pregnancy. Treatment efficacy, risks, and guidelines. New York, NY: Springer; 2014.Google Scholar
- 2.Gentile S. Anxiety and sleep disorders, psychopharmacology, and pregnancy. In: Galbally M, Snellen M, editors. Psychopharmacology and pregnancy. Treatment efficacy, risks, and guidelines. Berlin: Springer; 2014.Google Scholar
- 3.Calem M, Bisla J, Begum A, Dewey M, Bebbington PE, Brugha T, Cooper C, Jenkins R, Lindesay J, McManus S, Meltzer H, Spiers N, Weich S, Stewart R. Increased prevalence of insomnia and changes in hypnotics use in England over 15 years: analysis of the 1993, 2000, and 2007 national psychiatric morbidity surveys. Sleep. 2012;35:377–84.CrossRefPubMedGoogle Scholar
- 4.Dell'Osso B, Albert U, Atti AR, Carmassi C, Carrà G, Cosci F, Del Vecchio V, Di Nicola M, Ferrari S, Goracci A, Iasevoli F, Luciano M, Martinotti G, Nanni MG, Nivoli A, Pinna F, Poloni N, Pompili M, Sampogna G, Tarricone I, Tosato S, Volpe U, Fiorillo A. Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice. Neuropsychiatr Dis Treat. 2015;11:1885–909.PubMedCentralPubMedGoogle Scholar
- 8.Bellantuono C, Balestrieri M. Psicofarmacoterapia. In: Balestrieri M, Bellantuono C, Berardi D, Di Giannantonio M, Rigatelli M, Siracusano A, Zoccali RA, editors. Manuale di psichiatria. 2nd ed. Roma: Il Pensiero Scientifico Editore; 2014.Google Scholar
- 16.Ban L, West J, Gibson JE, Fiaschi L, Sokal R, Doyle P, Hubbard R, Smeeth L, Tata LJ. First trimester exposure to anxiolytic and hypnotic drugs and the risks of major congenital anomalies: a United Kingdom population-based cohort study. PLoS One. 2014;25(6):9.Google Scholar
- 25.Chisolm MS, Payne J. Management of psychotropic drugs during pregnancy. BMJ. 2015;351:5918.Google Scholar